× ×ª×× × ×ª×¨×פ×
××רש×
| ק×××¦× ×¤×¨×ק×××××ת (ATC4)
|
M09AX
Other drugs for disorders of the musculo-skeletal system
|
| ×ר××× ×¤×¢×× (ATC5)
|
Â
|
| צ×רת ×ת×
|
ת××-×ר××× - I.V
|
| צ×רת ××× ××
|
תר×××£, SUSPENSION
××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר××
|
| ×ת××××
|
Zolgensma is indicated for the treatment of:- patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1, or- patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene.
|
| × ×ª×× × ×ס×
|
ת×ר×× ××××× ×ס×
- 30/01/2020
|
×××××ת ×ס×
- תר××¤× ×××××ת ×ר×ש×× ×¢'× ×¨××¤× ××××× ×× ××××× ××רת
|
×ת×××× ×ס×
| ×ת×××× |
ת×ר×× ××××× |
ת××× ×§××× × |
Class Effect |
××¦× ×××× |
×ס×ס ×××××ת
|
| ×. ×תר××¤× ×ª×× ×ª× ×××פ×× ×××××× ×¢× ××× ×©× ×ª××× ×××ק×× ×× ×××× ×©×¨×ר×× ×ס×× spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. ×. ××××× ×××× ×××× ×ק×× ××פ×× ×ת×ש×ר ×× ×¤×¢× ××ת ××××× ×××ת×. ×. ××××× ××××ª× ×××× ×××× ×××× ×ק×× ××פ×× ×××ת ××תר×פ×ת â Nusinersen, Onasemnogene aberparvovec. סע××£ ×× ×× ×××× ×××¦× ×©× ××ש××× ××פ××× ×-Onasemnogene aberparvovec ש×× ×××× ××××× ×××××× ×©× ××× ××¨× ××××ר×ת ×ש××¢×ת×ת ×× ××× ×©×× ×¤×××©× ×ת ק×××¢× ×××צע×ת פ××× ×§× × ×× ×©×××. ×.×¢× ××£ ××××ר ×סע××£ ×, ×××× ×¢× ××× ×©× ×ª××× ×©××× ××פ×× ×-Nusinersen, ×××× ×××× ×ק×× ××פ×× ×-Onasemnogene aberparvovec, ××ת×× ××ª× ××× ×©×¤×ר××. ×.××ª× ×תר××¤× ×××¢×©× ××¤× ××¨×©× ×©× ××××× ×× ××ר×××××× ×××××, ××ר×××× ×שר ×××©×¨× ×¢× ××× ××× ×× ×צ××¨× ××צ××¢ ×פר×צ××ר×.
|
30/01/2020 |
× ××ר×××××× |
|
Spinal muscular atrophy, SMA |
|
| ×.×תר××¤× ×ª×× ×ª× ×××פ×× ×××××× ×¢× ××× ×©× ×ª××× ×××ק×× ×× ×××× ×©×¨×ר×× ×ס×× spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. ×.××××× ×××× ×××× ×ק×× ××פ×× ×ת×ש×ר ×× ×¤×¢× ××ת ××××× ×××ת×. ×. ××××× ××××ª× ×××× ×××× ×××× ×ק×× ××פ×× ×××ת ××תר×פ×ת â Nusinersen, Risdiplamת Onasemnogene aberparvovec. סע××£ ×× ×× ×××× ×××¦× ×©× ××ש××× ××פ××× ×-Onasemnogene aberparvovec ש×× ×××× ××××× ×××××× ×©× ××× ××¨× ××××ר×ת ×ש××¢×ת×ת ×× ××× ×©×× ×¤×××©× ×ת ק×××¢× ×××צע×ת פ××× ×§× × ×× ×©×××. ×. ×¢× ××£ ××××ר ×סע××£ ×, ×××× ×¢× ××× ×©× ×ª××× ×©××× ××פ×× ×-Nusinersen ×× Risdiplam, ×××× ×××× ×ק×× ××פ×× ×-Onasemnogene aberparvovec, ××ת×× ××ª× ××× ×©×¤×ר××. ×. ××ª× ×תר××¤× ×××¢×©× ××¤× ××¨×©× ×©× ××××× ×× ××ר×××××× ×××××, ××ר×××× ×שר ×××©×¨× ×¢× ××× ××× ×× ×צ××¨× ××צ××¢ ×פר×צ××ר×.
|
03/02/2022 |
× ××ר×××××× |
|
Spinal muscular atrophy, SMA |
|
|
ש×××ש ×ס×
-
|
×ס×רת ××××× ×ס×
- ×.×תר××¤× ×ª×× ×ª× ×××פ×× ×××××× ×¢× ××× ×©× ×ª××× ×××ק×× ×× ×××× ×©×¨×ר×× ×ס×× spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.
- ×.××××× ×××× ×××× ×ק×× ××פ×× ×ת×ש×ר ×× ×¤×¢× ××ת ××××× ×××ת×.
- ×. ××××× ××××ª× ×××× ×××× ×××× ×ק×× ××פ×× ×××ת ××תר×פ×ת â Nusinersen, Risdiplam ,Onasemnogene aberparvovec.
סע××£ ×× ×× ×××× ×××¦× ×©× ××ש××× ××פ××× ×-Onasemnogene aberparvovec ש×× ×××× ××××× ×××××× ×©× ××× ××¨× ××××ר×ת ×ש××¢×ת×ת ×× ××× ×©×× ×¤×××©× ×ת ק×××¢× ×××צע×ת פ××× ×§× × ×× ×©×××..
- ×. ×¢× ××£ ××××ר ×סע××£ ×, ×××× ×¢× ××× ×©× ×ª××× ×©××× ××פ×× ×-Nusinersen ×× Risdiplam, ×××× ×××× ×ק×× ××פ×× ×-Onasemnogene aberparvovec, ××ת×× ××ª× ××× ×©×¤×ר××.
- ×. ××ª× ×תר××¤× ×××¢×©× ××¤× ××¨×©× ×©× ××××× ×× ××ר×××××× ×××××, ××ר×××× ×שר ×××©×¨× ×¢× ××× ××× ×× ×צ××¨× ××צ××¢ ×פר×צ××ר×.
|
|
| ×ת××ת ××× ××
|
Posology and method of administration
|
| ×ת××××ת × ××
|
Contraindications
|
| ת×פע×ת ×××××
|
Undesirable effects
|
| ת××××ת ××× ×ª×¨×פת××ת
|
Interaction with other medicinal products and other forms of interaction
|
| ש×××ש ×××ר××× ××× ×§×
|
Pregnancy and Lactation
|
| פר×ק×××× ××ק×
|
Pharmacodynamic Properties
|
| פר×ק×ק×× ××ק×
|
Pharmacokinetic Properties
|
| ×¢××× ×ר××¤× ××××ר×ת ××¢×××
|
Â
Â
|
| ××פ×ש ×××ר××
|
×××ר×× ×-PubMed
|
| ××××¢ ×רשת
|
RxList WebMD Drugs.com
|
| ×©× ×צר×
|
NOVARTIS GENE THERAPIES, INC, USA
|
| ×©× ××¢× ×ר×ש××
|
NOVARTIS ISRAEL LTD
|
| ר×ש×××
|
ת×ר×× ××ש×: 6/2019. ר×ש××× ×ת×ר××:
|
| ת×ר×× ×¢×××× ××ר××
|
18/12/2025
|
ת×ר×× ×¢××××: 18/12/2025
NOVARTIS
××××'× ×¡×× - Zolgensma
true
השינוי האחרון נעשה בֹ־18 בדצמבר 2025 ב־13:24
